Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $1.6 million.

  • SAB Biotherapeutics' Other Accumulated Expenses fell 456.03% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 456.03%. This contributed to the annual value of $521639.0 for FY2024, which is 857.64% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Other Accumulated Expenses stood at $1.6 million for Q3 2025, which was down 456.03% from $808363.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Other Accumulated Expenses registered a high of $1.7 million during Q3 2024, and its lowest value of $200000.0 during Q1 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $411768.5 (2022), whereas its average is $571512.6.
  • Per our database at Business Quant, SAB Biotherapeutics' Other Accumulated Expenses plummeted by 4058.56% in 2023 and then surged by 70869.43% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Other Accumulated Expenses stood at $283909.0 in 2021, then surged by 80.73% to $513110.0 in 2022, then dropped by 6.37% to $480435.0 in 2023, then rose by 8.58% to $521639.0 in 2024, then soared by 210.72% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $808363.0 for Q2 2025, and $743100.0 during Q1 2025.